- Home
- MGRX vs ADVB Comparison
MGRX vs ADVB Comparison
Compare MGRX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- ADVB
- Stock Information
- Founded
- MGRX 2021
- ADVB 2014
- Country
- MGRX United States
- ADVB United States
- Employees
- MGRX N/A
- ADVB N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- ADVB Medical Specialities
- Sector
- MGRX Technology
- ADVB Health Care
- Exchange
- MGRX Nasdaq
- ADVB Nasdaq
- Market Cap
- MGRX 18.6M
- ADVB 20.8M
- IPO Year
- MGRX 2023
- ADVB 2025
- Fundamental
- Price
- MGRX $1.71
- ADVB $0.43
- Analyst Decision
- MGRX
- ADVB
- Analyst Count
- MGRX 0
- ADVB 0
- Target Price
- MGRX N/A
- ADVB N/A
- AVG Volume (30 Days)
- MGRX 145.9K
- ADVB 252.1K
- Earning Date
- MGRX 08-13-2025
- ADVB 08-11-2025
- Dividend Yield
- MGRX N/A
- ADVB N/A
- EPS Growth
- MGRX N/A
- ADVB N/A
- EPS
- MGRX N/A
- ADVB N/A
- Revenue
- MGRX $511,084.00
- ADVB N/A
- Revenue This Year
- MGRX N/A
- ADVB N/A
- Revenue Next Year
- MGRX N/A
- ADVB N/A
- P/E Ratio
- MGRX N/A
- ADVB N/A
- Revenue Growth
- MGRX N/A
- ADVB N/A
- 52 Week Low
- MGRX $1.32
- ADVB $0.42
- 52 Week High
- MGRX $7.66
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- MGRX 51.65
- ADVB N/A
- Support Level
- MGRX $1.61
- ADVB N/A
- Resistance Level
- MGRX $1.77
- ADVB N/A
- Average True Range (ATR)
- MGRX 0.14
- ADVB 0.00
- MACD
- MGRX 0.02
- ADVB 0.00
- Stochastic Oscillator
- MGRX 43.68
- ADVB 0.00
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.